Saiba selects AGC to manufacture COVID-19 vaccine

By The Science Advisory Board staff writers

June 16, 2020 -- Contract development and manufacturing organization AGC Biologics said it will be manufacturing a SARS-CoV-2 vaccine for Swiss biotechnology firm Saiba.

Saiba is leveraging its Cucumber Mosaic Virus virus-like particle (VLP) platform technology to develop the vaccine, according to AGC. The company said that the recombinant VLP vaccine has the potential to quickly deliver a prophylaxis for COVID-19, and also has a scalable, high-yield, large-scale production capability, the firm said.

AGC also noted that the vaccine has been engineered to enhance immune responsiveness in elderly people.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.